EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for chronic inflammatory diseases caused by epithelial dysfunction. Our unique approach centers around enhancing the integrity of the epithelial barrier to combat diseases like COPD and other lung conditions. Our lead compound, EP395, is an oral barrier-enhancing and anti-inflammatory drug that aims to reduce inflammation and slow disease progression.

With the potential to be a groundbreaking treatment option for COPD patients, EP395 offers hope for those suffering from irreversible airflow obstruction. As a pioneer in the field, EpiEndo Pharmaceuticals is developing a new class of oral drugs called Barriolides™. These innovative therapies have the potential to be first-in-class treatments for respiratory diseases and beyond.

Join us in our mission to transform lives by treating diseases caused by epithelial dysfunction. Learn more about our therapeutic pipeline, stay updated with our news and events, and explore career opportunities with our dedicated team. EpiEndo Pharmaceuticals, a breath of fresh air